Listen "CRISPR in 2025: Clinical Use, Regulatory Pressure, and Future Promise"
Episode Synopsis
Welcome back to Biotech Blueprint!In this week’s special episode, I teamed up with the Biotech Capital Compass to examine where gene editing stands today, scientifically, commercially, and clinically. This marks the start of a multi-part series on gene therapies, viewed through both scientific and investment lenses.Subscribe to Biotech Blueprint and Biotech Capital Compass.
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.